診断用放射性同位元素の世界市場

診断用放射性同位元素の世界市場は2030年までに56億米ドルに到達

2024年に42億米ドルと推定される診断用放射性同位元素の世界市場は、分析期間2024-2030年にCAGR 5.0%で成長し、2030年には56億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるテクネチウム-99mは、CAGR 4.1%を記録し、分析期間終了時には13億米ドルに達すると予測されます。タリウム-201セグメントの成長率は、分析期間中CAGR 4.1%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR7.7％で成長予測

米国の診断用放射性同位元素市場は2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 7.7%で推移し、2030年には市場規模が11億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と4.9％と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界の診断用放射性同位元素市場- 主要動向と促進要因のまとめ

なぜ診断用放射性同位元素は現代の医療画像診断に不可欠なのか？

診断用放射性同位元素は、臨床医が臓器、組織、細胞プロセスの機能を高い特異性と最小限の侵襲性で可視化し評価できるようにすることで、現代のヘルスケアにおいて重要な役割を果たしています。これらの放射性物質は、陽電子放射断層撮影法（PET）や単光子放射断層撮影法（SPECT）などの核医学イメージング技術に使用され、CTやMRIのような従来のイメージング・モダリティでは捉えることのできない代謝や機能に関する情報を提供します。例えば腫瘍学では、FDG-PETスキャンで使用されるFluorine-18のような診断用放射性同位元素は、悪性腫瘍の同定、がんの病期決定、治療効果のモニタリング、早期再発の検出に役立ちます。心臓病学では、テクネチウム-99mなどのアイソトープが冠動脈疾患や心機能を評価するための心筋灌流画像診断に使用されています。神経学的な応用としては、アルツハイマー病、てんかん、パーキンソン病の画像診断があり、構造的な異常が現れるずっと前に分子の変化を特定することができます。診断用放射性同位元素は、早期発見や精密な治療計画に不可欠な生理学的機能をリアルタイムで把握する能力で珍重されています。個別化医療が普及するにつれて、これらの薬剤は標的治療薬と併用されることが多くなり、診断と治療モニタリングを一つの連続体の中で組み合わせるセラノスティック・アプローチの基盤を形成しています。

放射性同位元素に基づく診断の能力は、技術の進歩によってどのように向上しているのか？

急速な技術革新は、ヘルスケアにおける診断用放射性同位元素の有効性、安全性、適用範囲を拡大しています。サイクロトロンと原子炉技術の開発により、主なアイソトープの生産効率と利用可能性が改善され、世界の供給課題に対処し、老朽化した原子炉への依存度が低下しています。ハイブリッドPET/CTやPET/MRIスキャナーのようなイメージング・ハードウェアの強化は、解剖学的データと機能的データの融合を可能にし、優れた診断精度をもたらし、より正確な疾患局在を可能にします。人工知能や高度な画像再構成アルゴリズムを含むソフトウェア主導の改良は、画像の解像度と定量化能力を高めながら、スキャン時間、放射線被曝、偽陽性の低減に役立っています。さらに、放射性医薬品化学は、がんバイオマーカーやアミロイド斑のような極めて特異的な生物学的標的に結合するようアイソトープを設計できるまでに進歩しており、その結果、高感度で疾患特異的な画像診断が可能となっています。放射性同位元素標識トレーサーを用いたコンパニオン診断薬は、標的治療薬と並行して開発され、適切な患者に適切な治療を提供することで、治療成績の向上とコスト削減を実現しています。放射性医薬品調製と品質管理の自動化により、アイソトープを用いた診断の再現性と拡張性が高まり、より広範な臨床応用が可能になりつつあります。これらの技術革新は、放射性同位元素を用いた、より正確で、個別化された、効率的な診断戦略への移行を後押ししています。

なぜ世界のヘルスケアシステムでラジオアイソトープ画像診断の臨床需要が高まっているのか？

慢性疾患の増加、人口の高齢化、早期かつ正確な診断の重要性の高まりにより、診断用放射性同位元素に対する臨床需要は世界中のヘルスケアシステムで急増しています。腫瘍学では、世界のがん罹患率の急増が、腫瘍の検出、病期分類、治療モニタリングのために放射性同位元素に大きく依存するPETおよびSPECTイメージングへの需要を煽っています。同様に、心血管疾患の有病率の上昇が、ルビジウム-82やタリウム-201などのアイソトープを用いた核ストレス検査や心筋灌流イメージングの必要性を高めています。神経学では、アルツハイマー病やパーキンソン病などの神経変性疾患の増加により、分子レベルでの病理学的変化を早期に検出できる放射性同位元素の利用が拡大しています。さらに、精密医療や標的治療アプローチの普及により、疾患の存在を確認し治療効果を予測するために、しばしば放射性同位元素標識薬剤を含むコンパニオン診断が必要とされています。診断用放射性同位元素はまた、小型で移動可能なイメージング・システムや簡略化された放射性トレーサー・プロトコルの開発により、外来患者や外来環境にもますます組み込まれるようになってきています。新興市場では、核医学インフラの改善とヘルスケア支出の増加により、ラジオアイソトープ診断の導入が加速しています。臨床医や政策立案者は、タイムリーで非侵襲的かつ正確な診断に価値を置いており、放射性同位元素の臨床需要は今後数年間で大幅に増加すると予想されます。

診断用放射性同位元素市場の世界的成長を加速する主な促進要因は？

診断用放射性同位元素市場の成長は、精密ヘルスケアにおける分子イメージングの役割の高まりを反映した、医療、技術、規制、経済の各要因の融合によってもたらされます。最も重要な要因の1つは、がん、心血管疾患、神経変性疾患の世界の負担増であり、早期かつ正確な診断が患者の予後を劇的に改善します。また、価値ベースのヘルスケアモデルへの継続的なシフトは、早期に治療方針を決定し、不必要な処置を減らし、治療効果を最適化できる診断方法の採用を医療提供者に促しています。サイクロトロンと放射性医薬品製造能力の拡大はアイソトープへのアクセスを改善し、特にアジア太平洋とラテンアメリカでは核医学インフラへの継続的な投資が新市場を開拓しています。FDAやEMAなどの規制機関は、放射性医薬品、特に新規治療薬のコンパニオン診断薬として開発された放射性医薬品の承認経路を加速させています。さらに、製薬会社と診断薬開発企業との戦略的提携は、放射性同位元素を標的治療の選択とモニタリングに使用するセラノスティクス分野を進展させています。教育イニシアティブや臨床研修プログラムも核医学の人材格差の解消に役立ち、採用をさらに後押ししています。世界のヘルスケアシステムが早期介入、医療費削減、個別化された患者ケアを目指す中、診断用放射性同位元素は次世代の医用画像診断と疾病管理を実現する重要な存在として位置づけられています。

セグメント

放射性同位元素の種類（テクネチウム-99m、タリウム-201、ガリウム-67、ヨウ素-123、FDG、ルビジウム-82、その他の放射性同位元素の種類）、診断用放射性同位元素（SPECT、PET、ベータエミッター）、用途（診断、治療）、最終用途（病院、専門クリニック、診断センター、学術・研究機関、その他の最終用途）

調査対象企業の例（注目の43社）

• Advanced Accelerator Applications
• Bayer AG
• Bracco Imaging S.p.A.
• BWX Technologies, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler AG
• GE HealthCare
• IBA Radiopharma Solutions
• Isotopia Molecular Imaging Ltd.
• Jubilant DraxImage Inc.
• Lantheus Holdings, Inc.
• Mallinckrodt Pharmaceuticals
• Nordion（Canada）Inc.
• NorthStar Medical Radioisotopes
• NTP Radioisotopes SOC Ltd.
• Orano Med LLC
• SHINE Technologies
• Siemens Healthineers AG
• Telix Pharmaceuticals Limited

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Diagnostic Radioisotopes Market to Reach US$5.6 Billion by 2030

The global market for Diagnostic Radioisotopes estimated at US$4.2 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Technetium-99m, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Thallium-201 segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.7% CAGR

The Diagnostic Radioisotopes market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Diagnostic Radioisotopes Market - Key Trends & Drivers Summarized

Why Are Diagnostic Radioisotopes Indispensable in Modern Medical Imaging?

Diagnostic radioisotopes play a critical role in contemporary healthcare by enabling clinicians to visualize and assess the function of organs, tissues, and cellular processes with high specificity and minimal invasiveness. These radioactive substances are used in nuclear medicine imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), which provide metabolic and functional information that traditional imaging modalities like CT and MRI cannot capture. For example, in oncology, diagnostic radioisotopes like Fluorine-18 (used in FDG-PET scans) help identify malignant tumors, determine cancer staging, monitor treatment efficacy, and detect early recurrence. In cardiology, isotopes such as Technetium-99m are used in myocardial perfusion imaging to evaluate coronary artery disease and cardiac function. Neurological applications include imaging for Alzheimer’s disease, epilepsy, and Parkinson’s disease, where molecular changes can be identified long before structural anomalies appear. Diagnostic radioisotopes are prized for their ability to provide real-time insights into physiological function, which is crucial for early detection and precision treatment planning. As personalized medicine gains traction, these agents are increasingly used in tandem with targeted therapies, forming the foundation of theranostic approaches that combine diagnostics with treatment monitoring in a single continuum.

How Are Technological Advancements Enhancing the Capabilities of Radioisotope-Based Diagnostics?

Rapid technological innovations are expanding the efficacy, safety, and reach of diagnostic radioisotope applications in healthcare. Developments in cyclotron and reactor technologies have improved the production efficiency and availability of key isotopes, addressing global supply challenges and reducing reliance on aging nuclear reactors. Enhanced imaging hardware, such as hybrid PET/CT and PET/MRI scanners, now allows for the fusion of anatomical and functional data, yielding superior diagnostic accuracy and enabling more precise localization of disease. Software-driven improvements, including artificial intelligence and advanced image reconstruction algorithms, are helping reduce scan times, radiation exposure, and false positives while enhancing image resolution and quantification capabilities. Moreover, radiopharmaceutical chemistry has advanced to the point where isotopes can be engineered to bind to highly specific biological targets, such as cancer biomarkers or amyloid plaques, resulting in highly sensitive and disease-specific imaging. Companion diagnostics using radiolabeled tracers are being developed alongside targeted therapies to ensure the right patients receive the right treatment, improving therapeutic outcomes and reducing costs. Automation in radiopharmaceutical preparation and quality control is also making isotope-based diagnostics more reproducible and scalable for broader clinical use. These innovations are collectively driving a transition toward more precise, personalized, and efficient diagnostic strategies using radioisotopes.

Why Is Clinical Demand for Radioisotope Imaging Rising Across Global Healthcare Systems?

Clinical demand for diagnostic radioisotopes is rising sharply across healthcare systems worldwide due to the increasing burden of chronic diseases, aging populations, and the growing emphasis on early and accurate diagnosis. In oncology, the global surge in cancer incidence is fueling demand for PET and SPECT imaging, which rely heavily on radioisotopes for tumor detection, staging, and therapy monitoring. Similarly, the rising prevalence of cardiovascular diseases is driving the need for nuclear stress tests and myocardial perfusion imaging using isotopes like Rubidium-82 and Thallium-201. In neurology, the increase in neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases has led to greater utilization of radioisotopes that can detect early pathological changes at the molecular level. Furthermore, the widespread adoption of precision medicine and targeted therapy approaches necessitates companion diagnostics that often involve radiolabeled agents to confirm disease presence and predict treatment response. Diagnostic radioisotopes are also being increasingly integrated into outpatient and ambulatory settings due to the development of compact, mobile imaging systems and simplified radiotracer protocols. In emerging markets, improvements in nuclear medicine infrastructure and growing healthcare expenditure are accelerating the adoption of radioisotope diagnostics. With clinicians and policymakers placing more value on timely, non-invasive, and accurate diagnostics, the clinical demand for radioisotopes is expected to rise substantially over the coming years.

What Are the Key Drivers Accelerating Global Growth in the Diagnostic Radioisotopes Market?

The growth in the diagnostic radioisotopes market is driven by a convergence of medical, technological, regulatory, and economic factors that reflect the increasing role of molecular imaging in precision healthcare. One of the most important drivers is the rising global burden of cancer, cardiovascular disease, and neurodegenerative disorders-conditions for which early and accurate diagnosis dramatically improves patient outcomes. The continued shift toward value-based healthcare models is also pushing providers to adopt diagnostic methods that can inform treatment decisions early, reduce unnecessary procedures, and optimize therapeutic efficacy. Expansion in cyclotron and radiopharmaceutical production capabilities is improving isotope accessibility, while ongoing investment in nuclear medicine infrastructure, especially in Asia-Pacific and Latin America, is opening new markets. Regulatory agencies like the FDA and EMA are accelerating the approval pathways for radiopharmaceuticals, particularly those developed as companion diagnostics for novel therapeutics. Moreover, strategic collaborations between pharmaceutical companies and diagnostic developers are advancing the theranostics field, where radioisotopes are used to select and monitor targeted therapies. Educational initiatives and clinical training programs are also helping bridge the talent gap in nuclear medicine, further supporting adoption. As global health systems strive for earlier intervention, lower healthcare costs, and personalized patient care, diagnostic radioisotopes are positioned as a critical enabler of the next generation of medical imaging and disease management.

SCOPE OF STUDY:

The report analyzes the Diagnostic Radioisotopes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Radioisotope Type (Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, Other Radioisotope Types); Diagnostic Radioisotope (SPECT, PET, Beta Emitters); Application (Diagnostic, Therapeutic); End-Use (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Advanced Accelerator Applications
• Bayer AG
• Bracco Imaging S.p.A.
• BWX Technologies, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler AG
• GE HealthCare
• IBA Radiopharma Solutions
• Isotopia Molecular Imaging Ltd.
• Jubilant DraxImage Inc.
• Lantheus Holdings, Inc.
• Mallinckrodt Pharmaceuticals
• Nordion (Canada) Inc.
• NorthStar Medical Radioisotopes
• NTP Radioisotopes SOC Ltd.
• Orano Med LLC
• SHINE Technologies
• Siemens Healthineers AG
• Telix Pharmaceuticals Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Diagnostic Radioisotopes - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growth in Molecular Imaging and Nuclear Medicine Throws the Spotlight on Diagnostic Radioisotope Demand
  • Rising Prevalence of Cancer and Cardiac Disorders Fuels Use of SPECT and PET Tracers
  • Aging Infrastructure and Reactor Downtime Challenges Create Opportunities for Cyclotron-Based Isotope Production
  • Regulatory Approvals of New PET Tracers Accelerate Adoption in Oncology, Neurology, and Cardiology
  • Push for Personalized Imaging Protocols Spurs Use of Radiolabeled Biomarkers in Patient Stratification
  • Growth in Theranostics Fuels Convergence of Diagnostic and Therapeutic Isotopes in Hybrid Applications
  • Global Shortage of Molybdenum-99 Highlights Demand for Diversified Isotope Sourcing Strategies
  • Investment in Generator-Based Delivery Systems Supports On-Site Production for Smaller Facilities
  • Rise in Outpatient Nuclear Imaging Clinics Drives Use of Short Half-Life Isotopes with Quick Turnaround
  • Integration with AI and Quantitative Imaging Analytics Enhances Data Interpretation in Radioisotope Scans
  • Push for Low-Radiation Dose Imaging Accelerates Development of High-Specificity Tracers
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Diagnostic Radioisotopes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Diagnostic Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Technetium-99m by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Technetium-99m by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Technetium-99m by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Thallium-201 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Thallium-201 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Thallium-201 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Gallium-67 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Gallium-67 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Gallium-67 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Iodine-123 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Iodine-123 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Iodine-123 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for FDG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for FDG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for FDG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Rubidium-82 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Rubidium-82 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Rubidium-82 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Radioisotope Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Beta Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for SPECT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for PET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for PET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for PET by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 92: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Diagnostic Radioisotopes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 119: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 155: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 230: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Diagnostic Radioisotopes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Diagnostic Radioisotopes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION